An Overview of the AM0010 Study in Kidney Cancer, Other Cancers

During a Targeted Oncology™ Case-Based Roundtable™ event, Manojkumar Bupathi, MD, MS, discussed with participants how risk groups affect their choice of first-line treatment in renal cell carcinoma. This is the first of 2 articles based on this event.

In season 2, episode 8 of Targeted Talks, Thomas Hutson, DO, PharmD, and Rana R. McKay, MD, discuss the renal cell carcinoma paradigm and challenges to overcome in the future.

In an interview with Targeted Oncology, Joshua K. Sabari, MD, discussed drug shortages and how they are affecting clinicians and patients in the oncology space.

Data from the phase 3 KEYNOTE-426 continue to support pembrolizumab plus axitinib as a standard of care for patients with clear cell renal cell carcinoma.

Thomas Hutson, DO, PharmD, FACP has updated reported efficacy results from the phase 2 CLEAR study.

The immunotherapy and tyrosine kinase inhibitor combination cabozantinib plus nivolumab and piplimumab induces response in nearly half of patients treated.